Hampel, P. J., Ding, W., Call, T. G., Rabe, K. G., Kenderian, S. S., Witzig, T. E., . . . Parikh, S. A. (2019). Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma.
Chicago ZitierstilHampel, Paul J., et al. "Rapid Disease Progression Following Discontinuation of Ibrutinib in Patients With Chronic Lymphocytic Leukemia Treated in Routine Clinical Practice." Leuk Lymphoma 2019.
MLA ZitierstilHampel, Paul J., et al. "Rapid Disease Progression Following Discontinuation of Ibrutinib in Patients With Chronic Lymphocytic Leukemia Treated in Routine Clinical Practice." Leuk Lymphoma 2019.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.